Chun-Te Wu1,2, Wei-Yu Lin2,3, Wen-Cheng Chen2,4, Miao-Fen Chen5,6. 1. Department of Urology, Chang Gung Memorial Hospital at Keelung, Keelung City, Taiwan. 2. College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Department of Urology, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan. 4. Department of Radiation Oncology, Chang Gung Memorial Hospital at Chiayi, Putz City, Chia-Yi Hsien, Taiwan. 5. College of Medicine, Chang Gung University, Taoyuan, Taiwan. miaofen@adm.cgmh.org.tw. 6. Department of Radiation Oncology, Chang Gung Memorial Hospital at Chiayi, Putz City, Chia-Yi Hsien, Taiwan. miaofen@adm.cgmh.org.tw.
Abstract
BACKGROUND: CD44, a cancer stem cell surface marker, is associated with treatment resistance and prognosis in some cancers. In the present study, we examined the predictive value of CD44 in muscle-invasive bladder cancer (MIBC). METHODS: We retrospectively analyzed the clinical outcomes of 105 MIBC patients and correlated these outcomes with the expression of CD44. Furthermore, the bladder cancer cell lines HT1197 and MB49 were selected for cellular and animal experiments to investigate the correlation between CD44 and tumor aggressiveness. RESULTS: Analysis of clinical specimens indicated that CD44 staining was significantly associated with a higher clinical stage, higher locoregional failure rate, and lower disease-specific survival rate for MIBC patients. Using cellular experiments and orthotopic tumor models, we showed that CD44+ bladder cancer cells had a higher invasion ability and augmented epithelial-mesenchymal transition (EMT) compared with CD44 cells. There was a significant correlation between interleukin (IL)-6 and CD44 levels noted by in vitro testing, and clinical samples. Blockade of IL-6 attenuated the expression of CD44, cancer stem-cell-like properties, and aggressive tumor behavior in vitro and in vivo. The related changes included the attenuated STAT3 activation and EMT, and decreased programmed death ligand 1-mediated T-cell suppression. CONCLUSION: Our findings suggest that CD44 expression is positively associated with tumor aggressiveness in bladder cancer, and activated IL-6 signaling provides a suitable microenvironment for the induction of CD44 expression.
BACKGROUND:CD44, a cancer stem cell surface marker, is associated with treatment resistance and prognosis in some cancers. In the present study, we examined the predictive value of CD44 in muscle-invasive bladder cancer (MIBC). METHODS: We retrospectively analyzed the clinical outcomes of 105 MIBCpatients and correlated these outcomes with the expression of CD44. Furthermore, the bladder cancer cell lines HT1197 and MB49 were selected for cellular and animal experiments to investigate the correlation between CD44 and tumor aggressiveness. RESULTS: Analysis of clinical specimens indicated that CD44 staining was significantly associated with a higher clinical stage, higher locoregional failure rate, and lower disease-specific survival rate for MIBCpatients. Using cellular experiments and orthotopic tumor models, we showed that CD44+ bladder cancer cells had a higher invasion ability and augmented epithelial-mesenchymal transition (EMT) compared with CD44 cells. There was a significant correlation between interleukin (IL)-6 and CD44 levels noted by in vitro testing, and clinical samples. Blockade of IL-6 attenuated the expression of CD44, cancer stem-cell-like properties, and aggressive tumor behavior in vitro and in vivo. The related changes included the attenuated STAT3 activation and EMT, and decreased programmed death ligand 1-mediated T-cell suppression. CONCLUSION: Our findings suggest that CD44 expression is positively associated with tumor aggressiveness in bladder cancer, and activated IL-6 signaling provides a suitable microenvironment for the induction of CD44 expression.
Authors: Hiroshi Fukushima; Baris Turkbey; Peter A Pinto; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: Joseph L Sottnik; Lauren Vanderlinden; Molishree Joshi; Ana Chauca-Diaz; Charles Owens; Donna E Hansel; Colin Sempeck; Debashis Ghosh; Dan Theodorescu Journal: Cancer Res Date: 2021-03-09 Impact factor: 13.312